Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Evaluation of a Plasma Marker (p-Tau217) for the Biological Diagnosis of Alzheimer's Disease, and Comparison With CSF Markers
Authors not listed
Centre Hospitalier Universitaire, Amiens · 2025
Abstract
The biological diagnosis of AD is actually performed by analysing Aβ1-40 and Aβ1-42 peptides, total tau and tau phosphorylated at Thr181 (p-Tau181) from cerebrospinal fluid (CSF) samples obtained by lumbar puncture (LP). Phospho-Tau 217 (p-Tau217) is a new biomarker that could be measured in plasma. The aim of this study is to compare the performances of plasma p-Tau217 with those of the reference CSF biomarkers in 150 patients recruited in the memory center of CHU Amiens (France). The study will be conducted during 18 months. The inclusion will be proposed to all patients for whom an indication of lumbar puncture / CSF is raised in a context of clinical suspicion of AD. During the daily hospitalization during which CSF will be collected for the "classical" biomarkers testing, a single tube of blood will be collected (anticoagulant EDTA, collected for p-Tau 217 analysis). The performances of CSF and plasma pTau 217 will be compared with the clinical diagnosis of AD (+, -, or indeterminate).
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-10 MST
Cite this
APA
Anonymous. (2025). Evaluation of a Plasma Marker (p-Tau217) for the Biological Diagnosis of Alzheimer's Disease, and Comparison With CSF Markers. <em>Centre Hospitalier Universitaire, Amiens</em>. https://clinicaltrials.gov/study/NCT07071649
Vancouver
Anonymous. Evaluation of a Plasma Marker (p-Tau217) for the Biological Diagnosis of Alzheimer's Disease, and Comparison With CSF Markers. Centre Hospitalier Universitaire, Amiens. 2025.
BibTeX
@misc{anon2025Evalua,
title = {Evaluation of a Plasma Marker (p-Tau217) for the Biological Diagnosis of Alzheimer's Disease, and Comparison With CSF Markers},
author = {Anonymous},
journal = {Centre Hospitalier Universitaire, Amiens},
year = {2025},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
European Respiratory Journal 2019
Open access · OA
Functional ageing in fibrotic interstitial lung disease: the impact of frailty on adverse health outcomes
Bengt Nellgård 2013
Open access · US-GOV
10-Year Follow-up of Mortality in Patients With Acute Hip Fractures: Associations With Pre-Alzheimer's/Alzheimer's Disease and Cerebrospinal Fluid Biomarkers
Wake Forest University Health Sciences 2018
Open access · US-GOV
Identifying Novel Aging Targets for Treatment of Delirium
Alzheimer's & dementia : the journal of the Alzheimer's Association 2026
Open access · OA
Epigenetic aging in Alzheimer's disease: Relation to proteome.
Assiut University 2016
Open access · US-GOV
Therapeutic Role of Transcranial Direct Current Stimulation (tDCS) in Alzheimer Patients, Double Blind Placebo Controlled Clinical Trial
Journal of Parkinson s Disease 2020
Preprint · OA